Announcements and Circulars – Cutia Therapeutics

2023.11.27	VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION COMPLETED DATABASE LOCK
2023.11.06	OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 AND THIRD QUARTER OF 2023
2023.11.02	VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) IN CHINA REACHED PRIMARY ENDPOINT
2023.10.25	VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION
2023.09.27	VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
2023.09.07	VOLUNTARY ANNOUNCEMENT - REGISTRATIONAL PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) REACHED PRIMARY ENDPOINT
2023.09.05	VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN THE LIST FOR SOUTHBOUND TRADING LINK UNDER THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT
2023.08.29	INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
2023.08.28	DISCLOSEABLE TRANSACTIONS - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS
2023.08.28	VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) COMPLETED DATABASE LOCK
2023.08.23	VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM)
2023.08.18	VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES
2023.08.17	DATE OF BOARD MEETING
2023.08.10	VOLUNTARY ANNOUNCEMENT - CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) HAS BEEN GRANTED PRIORITY REVIEW DESIGNATION BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
2023.08.02	OPERATIONAL UPDATE FOR THE SECOND QUARTER AND FIRST HALF OF 2023
2023.07.18	VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT)
2023.07.05	STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION
2023.06.09	LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2023.06.09	Terms of Reference for the Nomination Committee
2023.06.09	Terms of Reference for the Remuneration Committee
2023.06.09	Terms of Reference for the Audit Committee
2023.06.09	ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
2023.05.31	GLOBAL OFFERING
2023.05.31	GREEN APPLICATION FORM
2023.05.31	GLOBAL OFFERING (Multi-Files)
2023.05.31	GLOBAL OFFERING